Financial Condition Results Operations ITEM 8 Financial Statements Supplementary Data Years ended December 30 December 31 December 26 December 27 December 28 2017 2016 2015 2014 2013 thousands except per share data Income Statement Data Net sales 12,461,543 11,571,668 10,629,719 10,371,390 9,560,647 Gross profit 3,399,103 3,226,473 3,006,954 2,910,820 2,655,247 Selling general administrative expenses 5 2,539,734 2,409,008 2,238,051 2,195,678 1,978,193 Restructuring costs 1 45,891 34,931 Operating income 859,369 771,574 733,972 715,142 677,054 Other expense net 2 36,521 15,739 13,214 5,830 12,360 Income taxes equity earnings affiliates 822,848 755,835 720,758 709,312 664,694 Income taxes 3 362,506 217,958 211,391 215,610 190,891 Equity earnings affiliates 16,587 18,518 14,060 11,734 10,194 Loss sale equity investment 4 17,636 12,535 Net income 459,293 556,395 523,427 505,436 471,462 Less Net income attributable noncontrolling interests 52,994 49,617 44,369 39,359 39,908 Net income attributable Henry Schein Inc 406,299 506,778 479,058 466,077 431,554 Earnings per share attributable Henry Schein Inc 6 Basic 2.59 3.14 2.89 2.77 2.51 Diluted 2.57 3.10 2.85 2.72 2.46 Weighted-average common shares outstanding Basic 156,787 161,641 165,687 168,531 171,852 Diluted 158,208 163,723 168,250 171,480 175,244 43 Table Contents Years ended December 30 December 31 December 26 December 27 December 28 2017 2016 2015 2014 2013 thousands Net Sales Market Data Health care distribution 7 Dental 6,048,813 5,555,299 5,276,407 5,381,215 4,997,972 Animal health 3,476,635 3,253,095 2,921,624 2,898,612 2,599,461 Medical 2,497,994 2,337,661 2,072,915 1,742,685 1,643,167 Total health care distribution 12,023,442 11,146,055 10,270,946 10,022,512 9,240,600 Technology value-added services 8 438,101 425,613 358,773 348,878 320,047 Total 12,461,543 11,571,668 10,629,719 10,371,390 9,560,647 As December 30 December 31 December 26 December 27 December 28 2017 2016 2015 2014 2013 thousands Balance Sheet data Total assets 7,811,235 6,760,396 6,534,740 6,138,807 5,624,636 Long-term debt 907,756 715,457 463,752 542,776 450,233 Redeemable noncontrolling interests 832,138 607,636 542,194 564,527 497,539 Stockholders equity 2,824,410 2,800,804 2,886,814 2,816,445 2,788,001 1 Restructuring costs year ended December 31 2016 consist primarily severance costs including severance pay benefits 40.7 million facility closing costs 3.6 million costs 1.6 million Restructuring costs year ended December 26 2015 consist primarily severance costs including severance pay benefits 26.7 million facility closing costs 5.7 million costs 2.5 million See Management Discussion Analysis Financial Condition Results Operations Plans Restructuring herein consolidated financial statements related notes contained ITEM 8 2 Includes approximately 6.2 million one-time expenses related refinancing Henry Schein Animal Health debt 2013 These expenses reflect non-cash write-off deferred financing costs 3 In 2017 estimated one-time-charge 140 million related transition tax deemed repatriated foreign earnings one-time charge 3.0 million revaluation deferred taxes associated U.S tax reform legislation In 2015 6.3 million income tax benefit related favorable response tax petition allowed us conclude likely certain unrecognized tax benefits previously reserved would realized In 2013 13.4 million reduction valuation allowance related certain deferred tax assets related tax loss carryforwards originating outside United States 4 Represents 2017 loss divestiture equity ownership E4D Technologies 2013 loss divestiture noncontrolling interest dental wholesale distributor Middle East 5 Includes pre-tax charge 5,325 related litigation settlement 2017 6 On August 16 2017 announced Board Directors approved two-for-one stock split common stock Each Henry Schein Inc stockholder record close business September 1 2017 received distribution one additional share every share held Trading began split-adjusted basis September 15 2017 The effects stock split share per share amounts retroactively reflected periods presented Form 10-K 7 Consists consumable products small equipment laboratory products large equipment equipment repair services branded generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products vitamins 8 Consists practice management software value-added products distributed primarily health care providers financial services non-recourse basis e-services continuing education services practitioners consulting services 44 Table Contents ITEM 7 Management Discussion Analysis Financial Condition Results Operations Cautionary Note Regarding Forward-Looking Statements In accordance Safe Harbor provisions Private Securities Litigation Reform Act 1995 provide following cautionary remarks regarding important factors among others could cause future results differ materially forward-looking statements expectations assumptions expressed implied herein All forward-looking statements made us subject risks uncertainties guarantees future performance These forward-looking statements involve known unknown risks uncertainties factors may cause actual results performance achievements industry results materially different future results performance achievements expressed implied forward-looking statements These statements identified use terms may could expect intend believe plan estimate forecast project anticipate comparable terms Factors could cause contribute differences include limited discussed Annual Report Form 10-K particular risks discussed caption Risk Factors Item 1A report discussed documents file Securities Exchange Commission SEC Risk factors uncertainties could cause actual results differ materially current historical results include limited effects highly competitive consolidating market dependence third parties manufacture supply products dependence upon sales personnel customers suppliers manufacturers dependence senior management fluctuations quarterly earnings risks expansion customer purchasing power multi-tiered costing structures increases shipping costs products service issues third-party shippers general global macro-economic conditions risks associated currency fluctuations risks associated political economic uncertainty disruptions financial markets volatility market price common stock changes health care industry implementation health care laws failure comply regulatory requirements data privacy laws risks associated global operations transitional challenges associated acquisitions joint ventures including failure achieve anticipated synergies financial risks associated acquisitions joint ventures litigation risks new unanticipated litigation developments dependence continued product development technical support successful marketing technology segment dependence third parties certain technologically advanced components increased competition third party online commerce sites risks disruption information systems cyberattacks privacy data security breaches certain provisions governing documents may discourage third-party acquisitions us changes tax legislation The order factors appear construed indicate relative importance priority We caution factors may exhaustive many factors beyond ability control predict Accordingly forward-looking statements contained herein relied upon prediction actual results We undertake duty obligation update forward-looking statements Where You Can Find Important Information We may disclose important information one following channels SEC filings public conference calls webcasts press releases investor relations page website www.henryschein.com social media channels identified Newsroom page website Executive-Level Overview We believe world largest provider health care products services primarily office-based dental animal health medical practitioners We serve 1 million customers worldwide including dental practitioners laboratories animal health clinics physician practices well government institutional health care clinics alternate care clinics We believe strong brand identity due 85 years experience distributing health care products 45 Table Contents We headquartered Melville New York employ 22,000 people 11,400 based outside United States operations affiliates 34 countries including United States Australia Austria Belgium Brazil Canada Chile China Czech Republic Denmark France Germany Hong Kong SAR Ireland Israel Italy Japan Liechtenstein Luxembourg Malaysia Netherlands New Zealand Norway Poland Portugal Romania Slovakia South Africa Spain Sweden Switzerland Thailand United Arab Emirates United Kingdom We established strategically located distribution centers enable us better serve customers increase operating efficiency This infrastructure together broad product service offerings competitive prices strong commitment customer service enables us single source supply customers needs Our infrastructure also allows us provide convenient ordering rapid accurate complete order fulfillment We conduct business two reportable segments health care distribution ii technology value-added services These segments offer different products services customer base The health care distribution reportable segment aggregates global dental animal health medical operating segments This segment distributes consumable products small equipment laboratory products large equipment equipment repair services branded generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products vitamins Our global dental group serves office-based dental practitioners dental laboratories schools institutions Our global animal health group serves animal health practices clinics Our global medical group serves office-based medical practitioners ambulatory surgery centers alternate-care settings institutions Our global technology value-added services group provides software technology value-added services health care practitioners Our technology group offerings include practice management software systems dental medical practitioners animal health clinics Our value-added practice solutions include financial services non-recourse basis e-services practice technology network hardware services well continuing education services practitioners Industry Overview In recent years health care industry increasingly focused cost containment This trend benefited distributors capable providing broad array products services low prices It also accelerated growth HMOs group practices managed care accounts collective buying groups addition emphasis obtaining products competitive prices tend favor distributors capable providing specialized management information support We believe trend towards cost containment potential favorably affect demand technology solutions including software enhance efficiency facilitation practice management Our operating results recent years significantly affected strategies transactions undertook expand business domestically internationally part address significant changes health care industry including consolidation health care distribution companies health care reform trends toward managed care cuts Medicare collective purchasing arrangements Our current future results could impacted current economic environment uncertainty particularly impacting overall demand products services 46 Table Contents Industry Consolidation The health care products distribution industry relates office-based health care practitioners fragmented diverse This industry encompasses dental animal health medical markets estimated produce revenues approximately 45 billion 2017 global markets The industry ranges sole practitioners working relatively small offices group practices service organizations ranging size practitioners large number practitioners combined otherwise associated practices Due part inability office-based health care practitioners store manage large quantities supplies offices distribution health care supplies small equipment office-based health care practitioners characterized frequent small quantity orders need rapid reliable substantially complete order fulfillment The purchasing decisions within office-based health care practice typically made practitioner administrative assistant Supplies small equipment generally purchased one distributor one generally serving primary supplier The trend consolidation extends customer base Health care practitioners increasingly seeking partner affiliate combine larger entities hospitals health systems group practices physician hospital organizations In many cases purchasing decisions consolidated groups made centralized professional staff level however orders delivered practitioners offices We believe consolidation within industry continue result number distributors particularly limited financial operating marketing resources seeking combine larger companies provide growth opportunities This consolidation also may continue result distributors seeking acquire companies enhance current product service offerings provide opportunities serve broader customer base Our trend regard acquisitions joint ventures expand role provider products services health care industry This trend resulted expansion service areas complement existing operations provide opportunities us develop synergies thus strengthen acquired businesses As industry consolidation continues believe positioned capitalize trend believe ability support increased sales existing infrastructure although assurances able successfully accomplish We also invested expanding sales/marketing infrastructure include focus building relationships decision makers reside office-based practitioner setting As health care industry continues change continually evaluate possible candidates merger joint venture acquisition intend continue seek opportunities expand role provider products services health care industry There assurance able successfully pursue opportunity consummate transaction pursued If additional transactions entered consummated would incur merger and/or acquisition-related costs assurance integration efforts associated transaction would successful Aging Population Other Market Influences The health care products distribution industry continues experience growth due aging population increased health care awareness proliferation medical technology testing new pharmacology treatments expanded third-party insurance coverage partially offset effects unemployment insurance coverage In addition physician market continues benefit shift procedures diagnostic testing acute care settings alternate-care sites particularly physicians offices According U.S Census Bureau International Data Base 2017 six million Americans aged 85 years older segment population need long-term care elder-care 47 Table Contents services By year 2050 number projected nearly triple approximately 19 million The population aged 65 84 years projected increase 50 time period As result market dynamics annual expenditures health care services continue increase United States We believe demand products services grow continuing impacted current future operating economic industry conditions The Centers Medicare Medicaid Services CMS published National Health Expenditure Projections 2016-2025 indicating total national health care spending reached approximately 3.4 trillion 2016 18.1 nation gross domestic product benchmark measure annual production goods services United States Health care spending projected reach approximately 5.5 trillion 2025 approximately 19.9 nation gross domestic product Government Certain businesses involve distribution pharmaceuticals medical devices regard subject extensive local state federal foreign governmental laws regulations applicable distribution sale pharmaceuticals medical devices Additionally government private insurance programs fund large portion total cost medical care emphasis efforts control medical costs including laws regulations lowering reimbursement rates pharmaceuticals medical devices and/or medical treatments services Also many laws regulations subject change may impact financial performance In addition businesses generally subject numerous laws regulations could impact financial performance including securities antitrust anti-bribery anti-kickback customer interaction transparency data privacy data security laws regulations Failure comply law regulations could material adverse effect business Health Care Reform The United States Patient Protection Affordable Care Act amended Health Care Education Reconciliation Act enacted March 2010 Health Care Reform Law increased federal oversight private health insurance plans included number provisions designed reduce Medicare expenditures cost health care generally reduce fraud abuse provide access increased health coverage The Health Care Reform Law requirements include 2.3 excise tax domestic sales many medical devices manufacturers importers began 2013 fee branded prescription drugs biologics implemented 2011 may affect sales However respect medical device excise tax two-year moratorium imposed Consolidated Appropriations Act 2016 suspending imposition tax device sales period beginning January 1 2016 ending December 31 2017 January 22 2018 additional two-year moratorium imposed Public Law No 115-120 suspending imposition tax device sales period beginning January 1 2018 ending December 31 2019 The Health Care Reform Law also materially expanded number individuals United States health insurance The Health Care Reform Law faced ongoing legal challenges including litigation seeking invalidate law manner implemented In addition President seeking repeal replace Health Care Reform Law Repeal replace legislation passed House Representatives obtain necessary votes Senate Subsequently President affirmed intention repeal replace Health Care Reform Law taken number administrative actions materially weaken Health Care Reform Law On December 22 2017 President signed Tax Cuts Jobs Act law contains broad range tax reform provisions impact individual corporate tax rates international tax provisions income tax add-back provisions deductions The tax reform law also repealed individual mandate Health Care Reform Law The uncertain status Health Care Reform Law affects ability plan 48 Table Contents A Health Care Reform Law provision generally referred Physician Payment Sunshine Act Open Payments Program imposed new reporting disclosure requirements drug device manufacturers distributors regard payments transfers value made certain covered recipients including physicians dentists teaching hospitals manufacturers distributors group purchasing organizations regard certain ownership interests held physicians reporting entity CMS publishes information reports publicly available website including amounts transferred physician dentist teaching hospital identities Under Physician Payment Sunshine Act required collect report detailed information regarding certain financial relationships physicians dentists teaching hospitals We believe substantially compliant applicable Physician Payment Sunshine Act requirements The Physician Payment Sunshine Act pre-empts similar state reporting laws although subsidiaries may required report certain state transparency laws address circumstances covered Physician Payment Sunshine Act state laws well federal law ambiguous We also subject foreign regulations requiring transparency certain interactions suppliers customers While believe substantially compliant programs controls place comply requirements compliance rules imposes additional costs us Another notable Medicare health care reform initiative Medicare Access CHIP Reauthorization Act 2015 MACRA enacted April 16 2015 establishes new payment framework called Quality Payment Program modifies certain Medicare payments eligible clinicians including physicians dentists practitioners Under MACRA eligible clinicians required participate Medicare Merit-Based Incentive Payment System MIPS Advanced Alternative Payment Models APMs MIPS generally consolidate three current programs physician quality reporting system value-based payment modifier Medicare electronic health record EHR program single program Medicare reimbursement eligible clinicians include positive negative payment adjustments take account quality resource use clinical practice improvement meaningful use certified EHR technology Advanced APMs generally involve higher levels financial technology risk A final rule published Federal Register November 4 2016 allows eligible Medicare clinicians pick pace participation first performance period began January 1 2017 The data collected first performance year determine payment adjustments beginning January 1 2019 A final rule updating certain Quality Payment Program regulations published November 16 2017 became effective January 1 2018 MACRA represents fundamental change physician reimbursement expected provide substantial financial incentives physicians participate risk contracts increase physician information technology reporting obligations The implications implementation MACRA uncertain depend future regulatory activity physician activity marketplace MACRA may encourage physicians move smaller practices larger physician groups hospital employment leading consolidation portion customer base Although believe positioned capitalize consolidation trend assurances able successfully accomplish Health Care Fraud Certain businesses subject federal state similar foreign health care fraud abuse referral reimbursement laws regulations respect operations Some laws referred false claims laws prohibit submission causing submission false fraudulent claims reimbursement federal state health care payers programs Other laws referred anti-kickback laws prohibit soliciting offering receiving paying remuneration order induce referral patient ordering purchasing leasing arranging recommending ordering purchasing leasing items services paid federal state health care payers programs 49 Table Contents The fraud abuse laws regulations subject varying interpretations well heightened enforcement activity past years significant enforcement activity result relators serve whistleblowers filing complaints name United States applicable particular states federal state false claims laws Under federal False Claims Act relators entitled receive 30 total recoveries Also violations federal False Claims Act result treble damages accordance final rule published Department Justice February 3 2017 substantially increased maximum minimum civil penalties False Claims Act violations amounts civil penalties assessed February 3 2017 whose associated violations occurred November 2 2015 increased minimum per-claim penalty 10,781 10,957 maximum per-claim penalty 21,563 21,916 Most states adopted similar state false claims laws state laws penalties may addition federal False Claims Act penalties The Health Care Reform Law significantly strengthened federal False Claims Act federal Anti-Kickback Law provisions could lead possibility increased whistleblower relator suits among things made clear federal Anti-Kickback Law violation basis federal False Claims Act liability The United States government among others expressed concerns financial relationships suppliers one hand physicians dentists As result regularly review revise marketing practices necessary facilitate compliance We also subject certain United States foreign laws regulations concerning conduct foreign operations including U.S Foreign Corrupt Practices Act U.K Bribery Act German anti-corruption laws anti-bribery laws laws pertaining accuracy internal books records focus increasing enforcement activity globally recent years Failure comply fraud abuse laws regulations could result significant civil criminal penalties costs including loss licenses ability participate federal state health care programs could material adverse effect business Also measures may interpreted applied prosecutorial regulatory judicial authority manner could require us make changes operations incur substantial defense settlement expenses Even unsuccessful challenges regulatory authorities private relators could result reputational harm incurring substantial costs In addition many laws vague indefinite interpreted courts subject frequent modification varied interpretation prosecutorial regulatory authorities increasing risk noncompliance While believe substantially compliant applicable fraud abuse laws regulations adequate compliance programs controls place ensure substantial compliance cannot predict whether changes applicable law interpretation laws changes services marketing practices response changes applicable law interpretation laws could material adverse effect business Operating Security Licensure Standards Certain businesses involve distribution pharmaceuticals medical devices regard subject various local state federal foreign governmental laws regulations applicable distribution pharmaceuticals medical devices Among United States federal laws applicable us Controlled Substances Act Federal Food Drug Cosmetic Act amended FDC Act Section 361 Public Health Service Act We also subject comparable foreign regulations The FDC Act similar foreign laws generally regulate introduction manufacture advertising labeling packaging storage handling reporting marketing distribution record keeping pharmaceuticals medical devices shipped interstate commerce states may similarly regulate activities within state Section 361 Public Health Service Act provides authority prevent spread communicable diseases serves legal basis United States Food Drug Administration FDA regulation human cells tissues cellular tissue-based products also known HCT/P products 50 Table Contents The Federal Drug Quality Security Act 2013 brought significant changes respect pharmaceutical supply chain requirements pre-empts state law Title II measure known Drug Supply Chain Security Act DSCSA phased period ten years intended build national electronic interoperable system identify trace certain prescription drugs distributed United States The law track trace requirements applicable manufacturers wholesalers repackagers dispensers e.g pharmacies prescription drugs took effect January 2015 continue implemented The DSCSA product tracing requirements replace former FDA drug pedigree requirements pre-empt state requirements inconsistent stringent addition DSCSA requirements The DSCSA also establishes certain requirements licensing operation prescription drug wholesalers third party logistics providers 3PLs includes eventual creation national wholesaler 3PL licenses cases states license entities The DSCSA requires wholesalers 3PLs distribute drugs accordance certain standards regarding recordkeeping storage handling prescription drugs According FDA guidance states pre-empted imposing licensing requirements inconsistent less stringent directly related covered standards established federal law area Current state licensing requirements likely remain effect FDA issues new regulations directed DSCSA We believe substantially compliant applicable DSCSA requirements The Food Drug Administration Amendments Act 2007 Food Drug Administration Safety Innovation Act 2012 amended FDCA require FDA promulgate regulations implement unique device identification UDI system The FDA phasing implementation UDI regulations seven years generally beginning highest-risk devices i.e Class III medical devices ending lowest-risk devices The UDI regulations require labelers include unique device identifiers UDIs content format prescribed FDA issued system operated FDA-accredited issuing agency labels packages medical devices directly mark certain devices UDIs The UDI regulations also require labelers submit certain information concerning UDI-labeled devices FDA much information publicly available FDA database Global Unique Device Identification Database The UDI regulations provide certain exceptions alternatives time extensions For example UDI regulations include general exception Class I devices exempt Quality System Regulation record-keeping requirements complaint files Regulated labelers include entities device manufacturers repackagers reprocessors relabelers cause device label applied modified intent device commercially distributed without subsequent replacement modification label include certain businesses We believe substantially compliant applicable UDI requirements Under Controlled Substances Act distributor controlled substances required obtain renew annually registrations facilities United States Drug Enforcement Administration DEA permitting us handle controlled substances We also subject statutory regulatory requirements relating storage sale marketing handling distribution drugs accordance Controlled Substances Act implementing regulations requirements subject heightened enforcement activity recent times We subject inspection DEA Certain businesses also required register permits and/or licenses comply operating security standards DEA FDA United States Department Health Human Services various state boards pharmacy state health departments and/or comparable state agencies well comparable foreign agencies certain accrediting bodies depending type operations location product distribution manufacturing sale These businesses include distribute manufacture and/or repackage prescription pharmaceuticals and/or medical devices and/or HCT/P products pharmacy operations install maintain repair equipment In addition Section 301 National Organ Transplant Act number comparable state laws impose civil and/or criminal penalties transfer certain human tissue example human bone products valuable consideration generally permitting payments reasonable costs incurred procuring processing storing distributing tissue We also subject 51 Table Contents foreign government regulation products The DEA FDA state regulatory authorities broad inspection enforcement powers including ability suspend limit distribution products distribution centers seize order recall products impose significant criminal civil administrative sanctions violations laws regulations Foreign regulations subject us similar foreign enforcement powers Furthermore compliance legal requirements required may future require us institute voluntary recalls products sell could result financial losses potential reputational harm Our customers also subject significant federal state local foreign governmental regulation Certain businesses subject various additional federal state local foreign laws regulations including respect sale transportation storage handling disposal hazardous potentially hazardous substances safe working conditions Certain businesses also maintain contracts governmental agencies subject certain regulatory requirements specific government contractors Antitrust The U.S federal government U.S states many foreign countries antitrust laws prohibit certain types conduct deemed anti-competitive Violations antitrust laws result various sanctions including criminal civil penalties Private plaintiffs also could bring civil lawsuits us United States alleged antitrust law violations including claims treble damages Regulated Software Electronic Health Records The FDA become increasingly active addressing regulation computer software intended use health care settings developed continues develop policies regulating clinical decision support tools types software medical devices Certain businesses involve development sale software related products support physician dental practice management possible FDA foreign government authorities could determine one products medical device could subject us one businesses substantial additional requirements respect products In addition European Parliament Council European Union adopted new pan-European General Data Protection Regulation GDPR effective May 25 2018 increases privacy rights individuals Europe extends scope responsibilities data controllers data processors imposes increased requirements potential penalties companies offering goods services individuals located Europe Data Subjects monitoring behavior individuals including companies based outside Europe Noncompliance result penalties greater EUR 20 million 4 global company revenues Individual member states may impose additional requirements penalties relate certain things employee personal data Among things GDPR requires respect data concerning Data Subjects company accountability consents Data Subjects acceptable legal basis needed process personal data prompt breach notifications within 72 hours fairness transparency personal data stored used otherwise processed data integrity security provides rights Data Subjects relating modification erasure transporting personal data While expect substantially compliant programs controls place comply GDPR requirements compliance new regulation likely impose additional costs us cannot predict whether interpretations requirements changes practices response new requirements interpretations requirements could material adverse effect business We also sell products services health care providers physicians dentists use store manage patient medical dental records These customers subject laws regulations industry standards HIPAA Payment Card Industry Data Security Standards require protect privacy security records products may used part customers comprehensive data security programs including connection efforts comply applicable privacy security laws Perceived actual security vulnerabilities products services perceived actual failure us customers use products comply applicable legal contractual requirements may 52 Table Contents cause us significant reputational harm may also lead claims us customers and/or governmental agencies involve substantial fines penalties liabilities expenses costs remediation Federal initiatives provide program incentive payments available certain health care providers involving adoption use certain electronic health care records systems processes The initiatives include providing among others physicians dentists financial incentives meaningfully use certified EHR technology accordance applicable evolving requirements In addition Medicare-eligible providers fail timely adopt certified EHR systems meet meaningful use requirements systems accordance regulatory requirements subject cumulative Medicare reimbursement reductions reductions applicable health professionals including physicians dentists began January 1 2015 Qualification incentive payments requires use EHRs certain capabilities meaningful use pursuant evolving standards adopted CMS Office National Coordinator Health Information Technology ONC Department Health Human Services HHS The use certified EHR technology continue feature MACRA MIPS program connection Medicare EHR program payment adjustments eligible professionals sunset end 2018 MIPS payment adjustments begin January 1 2019 The first performance period MIPS began January 1 2017 afford eligible clinicians different reporting options linked amount data reported duration reporting period positive payment adjustments generally linked robust reporting On October 6 2015 CMS ONC released comprehensive final rules respect EHR program among things established challenging Stage 3 criteria made certain adjustments Stage 1 Stage 2 standards e.g reducing 2015 reporting period full year 90 days finalized 2015 edition health information technology HIT certification criteria added existing 2014 edition HIT certification criteria required 2018 Notably new rules compliance Stage 3 standards optional providers 2017 would generally required eligible providers regardless prior participation EHR incentive program 2018 reporting periods subsequently Developers others involved manufacture EHR program technology interim period develop certify products work customers implement products 2018 EHR program period In connection release October 6 rules HHS also stated continue modify applicable EHR program standards On November 14 2016 CMS published final rule impact Medicare Medicaid EHR incentive programs revisions objectives measures eligible hospitals critical access hospitals dual-eligible hospitals Certain businesses involve manufacture sale certified EHR systems products linked incentive programs CMS ONC establish criteria certified EHR systems criteria subject change In order maintain certification EHR products must satisfy changing governmental criteria Certain businesses involve manufacture sale certified EHR systems products linked incentive programs CMS ONC establish criteria certified EHR systems criteria subject change In order maintain certification EHR products must satisfy changing governmental criteria If EHR systems meet standards yet relied upon health care providers receive federal incentive payments noted exposed risk federal health care fraud abuse laws False Claims Act For example May 31 2017 U.S Department Justice announced 155 million settlement 5-year corporate integrity agreement involving vendor certified EHR systems based allegations vendor misrepresenting capabilities certifying body caused health care provider customers submit false Medicare Medicaid claims meaningful use payments violation False Claims Act While believe substantially compliance certifications applicable fraud abuse laws regulations adequate compliance programs controls place ensure substantial compliance cannot predict whether changes applicable law interpretation laws changes practices response changes applicable law interpretation laws could material adverse effect business Moreover order satisfy customers products may need incorporate increasingly complex reporting functionality Although believe positioned accomplish effort may involve increased costs failure implement product modifications otherwise satisfy applicable standards could material adverse effect 53 Table Contents business Other health information standards regulations HIPAA establish standards regarding electronic health data transmissions transaction code set rules specific electronic transactions transactions involving claims submissions third party payers Certain businesses provide electronic practice management products must meet requirements Failure abide electronic health data transmission standards could expose us breach contract claims substantial fines penalties liabilities expenses costs remediation harm reputation Additionally electronic medical devices increasingly connected technology ability connected systems safely effectively exchange use exchanged information becomes increasingly important On September 6 2017 FDA issued guidance assist industry identifying specific considerations related ability electronic medical devices safely effectively exchange use exchanged information As medical device manufacturer must manage risks including associated electronic interface incorporated medical device There may additional legislative initiatives future impacting health care 54 Table Contents E-Commerce Electronic commerce solutions become integral part traditional health care supply distribution relationships Our distribution business characterized rapid technological developments intense competition The continuing advancement online commerce requires us cost-effectively adapt changing technologies enhance existing services develop introduce variety new services address changing demands consumers customers timely basis particularly response competitive offerings Through proprietary technologically based suite products offer customers variety competitive alternatives We believe tradition reliable service name recognition large customer base built solid customer relationships position us well participate significant aspect distribution business We continue explore ways means improve expand Internet presence capabilities including online commerce offerings use various social media outlets Results Operations The following tables summarize significant components operating results cash flows three years ended December 30 2017 December 31 2016 December 26 2015 thousands Years Ended December 30 December 31 December 26 2017 2016 2015 Operating results Net sales 12,461,543 11,571,668 10,629,719 Cost sales 9,062,440 8,345,195 7,622,765 Gross profit 3,399,103 3,226,473 3,006,954 Operating expenses Selling general administrative 2,539,734 2,409,008 2,238,051 Restructuring costs 45,891 34,931 Operating income 859,369 771,574 733,972 Other expense net 36,521 15,739 13,214 Net income 459,293 556,395 523,427 Net income attributable Henry Schein Inc 406,299 506,778 479,058 Years Ended December 30 December 31 December 26 2017 2016 2015 Cash flows Net cash provided operating activities 545,515 642,576 615,500 Net cash used investing activities 342,276 316,422 260,031 Net cash used financing activities 112,551 327,344 348,030 Plans Restructuring On November 6 2014 announced corporate initiative rationalize operations provide expense efficiencies expected completed end fiscal 2015 This initiative originally planned elimination approximately 2 3 workforce closing certain facilities We subsequently announced plan extend restructuring activities end 2016 implement cost-savings initiatives ultimately resulted elimination approximately 900 positions representing slightly 4 workforce The total costs associated actions restructuring included 34.9 million pre-tax recorded fiscal 2015 45.9 million pre-tax recorded fiscal 2016 The costs associated restructuring included separate line item Restructuring costs within consolidated statements income As December 31 2016 restructuring activities complete incur additional restructuring charges fiscal 2017 55 Table Contents 2017 Compared 2016 Net Sales Net sales 2017 2016 follows thousands Increase 2017 Total 2016 Total Health care distribution 1 Dental 6,048,813 48.5 5,555,299 48.0 493,514 8.9 Animal health 3,476,635 27.9 3,253,095 28.1 223,540 6.9 Medical 2,497,994 20.1 2,337,661 20.2 160,333 6.9 Total health care distribution 12,023,442 96.5 11,146,055 96.3 877,387 7.9 Technology value-added services 2 438,101 3.5 425,613 3.7 12,488 2.9 Total 12,461,543 100.0 11,571,668 100.0 889,875 7.7 1 Consists consumable products small equipment laboratory products large equipment equipment repair services branded generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products vitamins 2 Consists practice management software value-added products distributed primarily health care providers financial services non-recourse basis e-services continuing education services practitioners consulting services The fiscal year ended December 30 2017 consisted 52 weeks compared fiscal year ended December 31 2016 consisted 53 weeks The 889.9 million 7.7 increase net sales year ended December 30 2017 includes increase 7.2 local currency growth 5.1 increase internally generated revenue 1.5 decrease due impact extra week 2016 3.6 growth acquisitions well increase 0.5 related foreign currency exchange The 493.5 million 8.9 increase dental net sales year ended December 30 2017 includes increase 7.9 local currencies 3.0 increase internally generated revenue 1.4 decrease due impact extra week 2016 6.3 growth acquisitions well increase 1.0 related foreign currency exchange The 7.9 increase local currency sales due increases dental equipment sales service revenues 4.5 6.5 increase internally generated revenue 2.4 decrease due impact extra week 2016 0.4 growth acquisitions dental consumable merchandise sales growth 9.0 1.9 increase internally generated revenue 1.1 decrease due impact extra week 2016 8.2 growth acquisitions The 223.6 million 6.9 increase animal health net sales year ended December 30 2017 includes increase 6.9 local currency growth 6.3 increase internally generated revenue 1.3 decrease due impact extra week 2016 1.9 growth acquisitions The growth internally generated animal health revenue affected revenue certain products recognized gross basis 2017 recognized agency basis prior year When excluding effects change internally generated revenue grew 6.0 The 160.3 million 6.9 increase medical net sales year ended December 30 2017 includes increase 6.8 local currency growth 8.4 increase internally generated revenue 1.6 decrease due impact extra week 2016 well increase 0.1 related foreign currency exchange The 12.5 million 2.9 increase technology value-added services net sales year ended December 30 2017 includes increase 3.2 local currency growth 3.5 increase internally generated revenue 0.8 decrease due impact extra week 2016 0.5 growth acquisitions partially offset decrease 0.3 related foreign currency exchange 56 Table Contents Gross Profit Gross profit gross margins 2017 2016 segment total follows thousands Gross Gross Increase 2017 Margin 2016 Margin Health care distribution 3,112,436 25.9 2,953,136 26.5 159,300 5.4 Technology value-added services 286,667 65.4 273,337 64.2 13,330 4.9 Total 3,399,103 27.3 3,226,473 27.9 172,630 5.4 Gross profit increased 172.6 million 5.4 year ended December 30 2017 compared prior year period As result different practices categorizing costs associated distribution networks throughout industry gross margins may necessarily comparable distribution companies Additionally realize substantially higher gross margin percentages technology segment health care distribution segment These higher gross margins result developer seller software products services well certain financial services The software industry typically realizes higher gross margins recover investments research development Within health care distribution segment gross profit margins may vary one period next Changes mix products sold well changes customer mix significant drivers affecting gross profit margin For example sales pharmaceutical products generally lower gross profit margins products Conversely sales private label products achieve gross profit margins higher average With respect customer mix sales large-group customers typically completed lower gross margins due higher volumes sold opposed gross margin sales office-based practitioners normally purchase lower volumes greater frequencies Health care distribution gross profit increased 159.3 million 5.4 year ended December 30 2017 compared prior year period Health care distribution gross profit margin decreased 25.9 year ended December 30 2017 26.5 comparable prior year period The overall increase health care distribution gross profit attributable 104.0 million gross profit increase growth internally generated revenue 125.3 million attributable acquisitions These increases partially offset 70.0 million decline gross profit due decrease gross margin rates Technology value-added services gross profit increased 13.3 million 4.9 year ended December 30 2017 compared prior year period Technology value-added services gross profit margin increased 65.4 year ended December 30 2017 64.2 comparable prior year period Acquisitions accounted 2.0 million gross profit increase within technology value-added services segment year ended December 30 2017 compared prior year period The remaining increase 11.3 million technology value-added services segment gross profit primarily attributable growth internally generated revenue increase gross margin rates Selling General Administrative Selling general administrative expenses segment total 2017 2016 follows thousands Respective Respective Increase 2017 Net Sales 2016 Net Sales Health care distribution 2,383,916 19.8 2,256,948 20.2 126,968 5.6 Technology value-added services 155,818 35.6 152,060 35.7 3,758 2.5 Total 2,539,734 20.4 2,409,008 20.8 130,726 5.4 Selling general administrative expenses increased 130.7 million 5.4 year ended December 30 2017 comparable prior year period The 127.0 million increase selling general administrative expenses within health care distribution segment year ended December 30 2017 compared prior year period attributable 107.3 million additional costs acquired companies 19.7 million additional operating costs The 3.7 million increase selling general administrative expenses within 57 Table Contents technology value-added services segment year ended December 30 2017 compared prior year period attributable 2.1 million additional costs acquired companies 1.6 million additional operating costs As percentage net sales selling general administrative expenses decreased 20.4 20.8 comparable prior year period As component total selling general administrative expenses selling expenses increased 82.2 million 5.6 year ended December 30 2017 comparable prior year period As percentage net sales selling expenses decreased 12.5 12.8 comparable prior year period As component total selling general administrative expenses general administrative expenses increased 48.5 million 5.2 year ended December 30 2017 comparable prior year period As percentage net sales general administrative expenses decreased 7.8 8.0 comparable prior year period Other Expense Net Other expense net years ended 2017 2016 follows thousands Variance 2017 2016 Interest income 17,553 13,275 4,278 32.2 Interest expense 53,654 31,893 21,761 68.2 Other net 420 2,879 3,299 114.6 Other expense net 36,521 15,739 20,782 132.0 Other expense net increased 20.8 million 36.5 million year ended December 30 2017 comparable prior year period Interest income increased 4.3 million primarily due increased investment late fee income Interest expense increased 21.8 million primarily due increased borrowings higher interest rates bank credit lines interest expense related financing arrangement entered first quarter 2017 Brazil Other net decreased 3.3 million due primarily investment proceeds received first quarter 2016 Income Taxes For year ended December 30 2017 effective tax rate 44.1 compared 28.8 prior year period Our effective tax rate 2017 primarily higher due Tax Cuts Jobs Act Tax Act Our effective tax rate favorably impacted 2017 adoption Accounting Standards Update ASU 2016-09 Accounting Stock Compensation well savings implementation tax planning initiatives higher income lower tax jurisdictions During second quarter 2016 effective tax rate affected federal tax audit settlement reduced income tax expense approximately 4.5 million For 2018 expect effective tax rate range 24 On December 22 2017 U.S government passed Tax Cuts Jobs Act Tax Act The Tax Act comprehensive tax legislation implements complex changes U.S tax code including limited reduction corporate tax rate 35 21 modification accelerated depreciation repeal domestic manufacturing deduction changes limitations deductibility interest Additionally Tax Act moves global tax regime modified territorial regime requires U.S companies pay mandatory one-time transition tax historical offshore earnings repatriated U.S The transition tax payable eight years Due complexities Tax Act SEC staff issued Staff Accounting Bulletin No 118 SAB 118 allows company record provisional amount income tax effects Tax Act accordance ASC 740 extent reasonable estimate made SAB 118 allows measurement period one year enactment date Tax Act finalize recording related tax impacts We recorded provisional amounts items could reasonably estimated time This includes one-time transition tax estimated 140.0 million Within consolidated balance sheets 27.4 million included Accrued taxes 112.6 million included Other liabilities The U.S 58 Table Contents deferred tax assets liabilities revalued due lower enacted federal income tax rate 21 effective January 1 2018 The Company accrued net deferred tax expense 3.0 million attributable revaluation In aggregate quarter ended December 30 2017 Tax Act modifications resulted one-time tax expense approximately 143.0 million Absent effects transition tax revaluation deferred tax assets liabilities effective tax rate year ended December 30 2017 would 26.7 compared actual effective tax rate 44.1 The Tax Act also includes provisions tax global intangible low-taxed income GILTI base erosion anti-abuse tax BEAT imposes tax certain foreign related-party payments The Company subject GILTI BEAT provisions effective January 1 2018 The Company process assessing effects provisions 2018 The ultimate impacts Tax Act may differ estimate possibly materially due additional guidance U.S Department Treasury updates changes assumptions revision accounting standards income taxes related interpretations future information may become available We currently anticipate finalizing recording resulting adjustments quarter ended September 29 2018 If information necessary finalize record related tax impacts available prior quarter ended September 29 2018 book impacts accordingly Net Income Net income decreased 97.1 million 17.5 year ended December 30 2017 compared prior year period due factors noted 59 Table Contents 2016 Compared 2015 Net Sales Net sales 2016 2015 follows thousands Increase 2016 Total 2015 Total Health care distribution 1 Dental 5,555,299 48.0 5,276,407 49.6 278,892 5.3 Animal health 3,253,095 28.1 2,921,624 27.5 331,471 11.3 Medical 2,337,661 20.2 2,072,915 19.5 264,746 12.8 Total health care distribution 11,146,055 96.3 10,270,946 96.6 875,109 8.5 Technology value-added services 2 425,613 3.7 358,773 3.4 66,840 18.6 Total 11,571,668 100.0 10,629,719 100.0 941,949 8.9 1 Consists consumable products small equipment laboratory products large equipment equipment repair services branded generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products vitamins 2 Consists practice management software value-added products distributed primarily health care providers financial services non-recourse basis e-services continuing education services practitioners consulting services The fiscal year ended December 31 2016 consisted 53 weeks compared fiscal year ended December 26 2015 consisted 52 weeks The 941.9 million 8.9 increase net sales year ended December 31 2016 includes increase 10.1 local currency growth 6.7 increase internally generated revenue 1.5 impact extra week 1.9 growth acquisitions partially offset decrease 1.2 related foreign currency exchange The 278.9 million 5.3 increase dental net sales year ended December 31 2016 includes increase 6.2 local currencies 3.2 increase internally generated revenue 1.5 impact extra week 1.5 growth acquisitions offset decrease 0.9 related foreign currency exchange The 6.2 increase local currency sales due increases dental equipment sales service revenues 9.0 5.1 increase internally generated revenue 2.5 impact extra week 1.4 growth acquisitions dental consumable merchandise sales growth 5.3 2.6 increase internally generated revenue 1.2 impact extra week 1.5 growth acquisitions The 331.5 million 11.3 increase animal health net sales year ended December 31 2016 includes increase 13.9 local currency growth 9.6 increase internally generated revenue 1.5 impact extra week 2.8 growth acquisitions partially offset decrease 2.6 related foreign currency exchange The growth internally generated animal health revenue affected revenue certain products recognized gross basis 2016 recognized agency basis prior year When excluding effects change internally generated revenue grew 7.1 The 264.7 million 12.8 increase medical net sales year ended December 31 2016 includes increase 12.8 local currency growth 11.1 increase internally generated revenue 1.7 impact extra week The growth internally generated medical revenue affected certain sales recognized gross basis 2016 recognized agency basis prior year When excluding effects change internally generated revenue grew 7.9 The 66.8 million 18.6 increase technology value-added services net sales year ended December 31 2016 includes increase 20.0 local currency growth 7.9 increase internally generated revenue 0.9 impact extra week 11.2 growth acquisitions partially offset decrease 1.4 related foreign currency exchange 60 Table Contents Gross Profit Gross profit gross margins 2016 2015 segment total follows thousands Gross Gross Increase 2016 Margin 2015 Margin Health care distribution 2,953,136 26.5 2,768,627 27.0 184,509 6.7 Technology value-added services 273,337 64.2 238,327 66.4 35,010 14.7 Total 3,226,473 27.9 3,006,954 28.3 219,519 7.3 Gross profit increased 219.5 million 7.3 year ended December 31 2016 compared prior year period As result different practices categorizing costs associated distribution networks throughout industry gross margins may necessarily comparable distribution companies Additionally realize substantially higher gross margin percentages technology segment health care distribution segment These higher gross margins result developer seller software products services well certain financial services The software industry typically realizes higher gross margins recover investments research development Within health care distribution segment gross profit margins may vary one period next Changes mix products sold well changes customer mix significant drivers affecting gross profit margin For example sales pharmaceutical products generally lower gross profit margins products Conversely sales private label products achieve gross profit margins higher average With respect customer mix sales large-group customers typically completed lower gross margins due higher volumes sold opposed gross margin sales office-based practitioners normally purchase lower volumes greater frequencies Health care distribution gross profit increased 184.5 million 6.7 year ended December 31 2016 compared prior year period Health care distribution gross profit margin decreased 26.5 year ended December 31 2016 27.0 comparable prior year period The overall increase health care distribution gross profit attributable 170.8 million gross profit increase growth internally generated revenue 60.9 million attributable acquisitions These increases partially offset 47.2 million decline gross profit due primarily effects foreign exchange revenues decrease gross margin rates Technology value-added services gross profit increased 35.0 million 14.7 year ended December 31 2016 compared prior year period Technology value-added services gross profit margin decreased 64.2 year ended December 31 2016 66.4 comparable prior year period Acquisitions accounted 18.5 million gross profit increase within technology value-added services segment year ended December 31 2016 compared prior year period The remaining increase 16.5 million technology value-added services segment gross profit primarily attributable growth internally generated revenue 61 Table Contents Selling General Administrative Selling general administrative expenses segment total 2016 2015 follows thousands Respective Respective Increase 2016 Net Sales 2015 Net Sales Health care distribution 2,256,948 20.2 2,108,164 20.5 148,784 7.1 Technology value-added services 152,060 35.7 129,887 36.2 22,173 17.1 Total 2,409,008 20.8 2,238,051 21.1 170,957 7.6 Selling general administrative expenses increased 171.0 million 7.6 year ended December 31 2016 comparable prior year period The 148.8 million increase selling general administrative expenses within health care distribution segment year ended December 31 2016 compared prior year period attributable 57.6 million additional costs acquired companies 91.2 million additional operating costs The 22.2 million increase selling general administrative expenses within technology value-added services segment year ended December 31 2016 compared prior year period attributable 15.3 million additional costs acquired companies 6.9 million additional operating costs As percentage net sales selling general administrative expenses decreased 20.8 21.1 comparable prior year period As component total selling general administrative expenses selling expenses increased 104.3 million 7.6 year ended December 31 2016 comparable prior year period As percentage net sales selling expenses decreased 12.8 13.0 comparable prior year period As component total selling general administrative expenses general administrative expenses increased 66.7 million 7.7 year ended December 31 2016 comparable prior year period As percentage net sales general administrative expenses decreased 8.0 8.1 comparable prior year period Other Expense Net Other expense net years ended 2016 2015 follows thousands Variance 2016 2015 Interest income 13,275 12,935 340 2.6 Interest expense 31,893 26,008 5,885 22.6 Other net 2,879 141 3,020 2,141.8 Other expense net 15,739 13,214 2,525 19.1 Other expense net increased 2.5 million 15.7 million year ended December 31 2016 comparable prior year period Interest expense increased 5.9 million primarily due increased borrowings bank credit lines U.S trade accounts receivable securitization Higher interest rates also contributed increase interest expense Other net increased 3.0 million due primarily investment proceeds received first quarter 2016 Income Taxes For year ended December 31 2016 effective tax rate 28.8 compared 29.3 prior year period During second quarter 2016 effective tax rate affected federal tax audit settlement reduced income tax expense approximately 4.5 million During third quarter 2015 received favorable response tax petition allowed us conclude likely certain unrecognized tax benefits previously reserved would realized As result provision income taxes 2015 included 6.3 million income tax benefit 62 Table Contents Absent effects income tax benefit third quarter 2015 effective tax rate year ended December 26 2015 would 30.2 compared actual effective tax rate 29.3 The remaining difference effective tax rate federal statutory tax rate periods primarily relates state foreign income taxes interest expense Net Income Net income increased 33.0 million 6.3 year ended December 31 2016 compared prior year period due factors noted 63 Table Contents Liquidity Capital Resources Our principal capital requirements include funding acquisitions purchases additional noncontrolling interests repayments debt principal funding working capital needs purchases fixed assets repurchases common stock Working capital requirements generally result increased sales special inventory forward buy-in opportunities payment terms receivables payables Historically sales tended stronger third fourth quarters special inventory forward buy-in opportunities prevalent end year caused working capital requirements higher end third quarter end first quarter following year We finance business primarily cash generated operations revolving credit facilities debt placements Our ability generate sufficient cash flows operations dependent continued demand customers products services access products services suppliers Our business requires substantial investment working capital susceptible fluctuations year result inventory purchase patterns seasonal demands Inventory purchase activity function sales activity special inventory forward buy-in opportunities desired level inventory We anticipate future increases working capital requirements We finance business provide adequate funding least 12 months Funding requirements based forecasted profitability working capital needs occasion may change Consequently may change funding structure reflect new requirements We believe cash cash equivalents ability access private debt markets public equity markets available funds existing credit facilities provide us sufficient liquidity meet currently foreseeable short-term long-term capital needs We off-balance sheet arrangements Net cash provided operating activities 545.5 million year ended December 30 2017 compared 642.6 million prior year The net change 97.1 million primarily attributable working capital requirements Net cash used investing activities 342.3 million year ended December 30 2017 compared 316.4 million prior year The net change 25.9 million primarily due increased payments equity investments business acquisitions partially offset proceeds sales equity investments Net cash used financing activities 112.6 million year ended December 30 2017 compared 327.3 million prior year The net change 214.7 million primarily due increased net borrowings debt decreased repurchases common stock decreased acquisitions noncontrolling interests subsidiaries The following table summarizes selected measures liquidity capital resources thousands December 30 December 31 2017 2016 Cash cash equivalents 174,658 62,381 Working capital 1,257,045 1,022,134 Debt Bank credit lines 741,653 437,476 Current maturities long-term debt 16,659 65,923 Long-term debt 907,756 715,457 Total debt 1,666,068 1,218,856 Our cash cash equivalents consist bank balances investments money market funds representing overnight investments high degree liquidity 64 Table Contents Accounts receivable days sales outstanding inventory turns Our accounts receivable days sales outstanding operations decreased 41.2 days December 30 2017 41.3 days December 31 2016 During years ended December 30 2017 December 31 2016 wrote approximately 6.7 million 6.2 million respectively fully reserved accounts receivable trade receivable reserve Our inventory turns operations 5.3 December 30 2017 5.5 December 31 2016 Our working capital accounts may impacted current future economic conditions Contractual obligations The following table summarizes contractual obligations related fixed variable rate long-term debt including interest assuming weighted average interest rate 2.7 well inventory purchase commitments operating capital lease obligations December 30 2017 Payments due period thousands 1 year 2 3 years 4 5 years 5 years Total Contractual obligations Long-term debt including interest 42,750 513,207 163,687 345,618 1,065,262 Inventory purchase commitments 232,479 507,324 242,394 982,197 Operating lease obligations 94,038 131,461 68,446 64,674 358,619 Transition tax obligations 27,400 21,400 30,900 60,300 140,000 Capital lease obligations including interest 1,678 1,426 628 1,799 5,531 Total 398,345 1,174,818 506,055 472,391 2,551,609 Bank Credit Lines On April 18 2017 entered new 750 million revolving credit agreement Credit Agreement This facility matures April 2022 replaced 500 million revolving credit facility scheduled mature September 2019 The interest rate based USD LIBOR plus spread based leverage ratio end financial reporting quarter The Credit Agreement provides among things required maintain maximum leverage ratios contains customary representations warranties affirmative covenants The Credit Agreement also contains customary negative covenants subject negotiated exceptions liens indebtedness significant corporate changes including mergers dispositions certain restrictive agreements As December 30 2017 December 31 2016 borrowings outstanding revolving credit facility prior credit facility 320.0 million 65.0 million respectively As December 30 2017 December 31 2016 11.3 million 13.0 million letters credit respectively provided third parties credit facility prior credit facility As December 30 2017 December 31 2016 various short-term bank credit lines available 421.7 million 372.5 million respectively outstanding At December 30 2017 December 31 2016 borrowings credit lines weighted average interest rate 2.27 1.61 respectively Private Placement Facilities On September 15 2017 increased available private placement facilities three insurance companies total facility amount 1 billion extended expiration date September 15 2020 These facilities available uncommitted basis fixed rate economic terms agreed upon time issuance time time September 15 2020 The facilities allow us issue senior promissory notes lenders fixed rate based agreed upon spread applicable treasury notes time issuance The term possible issuance selected us range five 15 years average life longer 12 years The proceeds issuances facilities used general corporate purposes including working capital capital expenditures refinance existing indebtedness and/or fund potential acquisitions The agreements provide among things maintain certain maximum leverage ratios 65 Table Contents contain restrictions relating subsidiary indebtedness liens affiliate transactions disposal assets certain changes ownership These facilities contain make-whole provisions event pay facilities prior applicable due dates The components private placement facility borrowings December 30 2017 presented following table thousands Amount Date Borrowing Borrowing Borrowing Outstanding Rate Due Date September 2 2010 100,000 3.79 September 2 2020 January 20 2012 50,000 3.45 January 20 2024 January 20 2012 1 35,714 3.09 January 20 2022 December 24 2012 50,000 3.00 December 24 2024 June 2 2014 100,000 3.19 June 2 2021 June 16 2017 100,000 3.42 June 16 2027 September 15 2017 100,000 3.52 September 15 2029 Less Deferred debt issuance costs 419 535,295 1 Annual repayments approximately 7.1 million borrowing commenced January 20 2016 U.S Trade Accounts Receivable Securitization We facility agreement bank agent based securitization U.S trade accounts receivable structured asset-backed securitization program pricing committed three years On June 1 2016 extended expiration date facility agreement April 29 2019 increased purchase limit facility 300 million 350 million On July 6 2017 extended expiration date facility agreement April 29 2020 The borrowings outstanding securitization facility 350.0 million 350.0 million December 30 2017 December 31 2016 respectively At December 30 2017 interest rate borrowings facility based asset-backed commercial paper rate 153 basis points plus 75 basis points combined rate 2.28 At December 31 2016 interest rate borrowings facility based asset-backed commercial paper rate 101 basis points plus 75 basis points combined rate 1.76 We required pay commitment fee 30 basis points daily balance unused portion facility usage greater equal 50 facility limit commitment fee 35 basis points daily balance unused portion facility usage less 50 facility limit Borrowings facility presented component Long-term debt within consolidated balance sheet 66 Table Contents Long-term debt Long-term debt consisted following December 30 December 31 2017 2016 Private placement facilities 535,295 342,857 U.S trade accounts receivable securitization 350,000 350,000 Note payable bank weighted average interest rate 21.37 December 31 2016 47,957 Various collateralized uncollateralized loans payable interest varying installments 2022 interest rates ranging 2.56 12.90 December 30 2017 ranging 2.56 12.90 December 31 2016 34,027 35,150 Capital lease obligations see Note 17 5,093 5,416 Total 924,415 781,380 Less current maturities 16,659 65,923 Total long-term debt 907,756 715,457 Stock repurchases From June 21 2004 December 30 2017 repurchased approximately 2.7 billion 55,670,990 shares common stock repurchase programs 200.0 million available December 30 2017 future common stock share repurchases Redeemable noncontrolling interests Some minority stockholders certain subsidiaries right certain times require us acquire ownership interest entities fair value Accounting Standards Codification Topic 480-10 applicable noncontrolling interests may required purchase portion outstanding interest consolidated subsidiary noncontrolling interest holder terms put option contained contractual agreements The components change Redeemable noncontrolling interests years ended December 30 2017 December 31 2016 December 26 2015 presented following table December 30 December 31 December 26 2017 2016 2015 Balance beginning period 607,636 542,194 564,527 Decrease redeemable noncontrolling interests due redemptions 48,669 72,729 82,563 Increase redeemable noncontrolling interests due business acquisitions 78,939 58,172 18,936 Net income attributable redeemable noncontrolling interests 52,203 48,760 43,588 Dividends declared 28,161 32,973 32,706 Effect foreign currency translation gain loss attributable redeemable noncontrolling interests 7,461 2,652 4,790 Change fair value redeemable securities 162,729 66,864 35,202 Balance end period 832,138 607,636 542,194 Changes estimated redemption amounts noncontrolling interests subject put options adjusted reporting period corresponding adjustment Additional paid-in capital Future reductions carrying amounts subject floor amount equal fair value redeemable noncontrolling interests time originally recorded The recorded value redeemable noncontrolling interests cannot go floor level These adjustments impact calculation earnings per share 67 Table Contents Additionally prior owners acquired subsidiaries eligible receive additional purchase price cash consideration certain financial targets met Any adjustments accrual amounts recorded consolidated statement income Unrecognized tax benefits As fully disclosed Note 12 Notes Consolidated Financial Statements cannot reasonably estimate timing future cash flows related unrecognized tax benefits including accrued interest 105.2 million December 30 2017 Critical Accounting Policies Estimates The preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures contingent assets liabilities We base estimates historical data available experience industry market trends various assumptions believed reasonable circumstances combined results form basis making judgments carrying values assets liabilities readily apparent sources However nature estimates subject various assumptions uncertainties Reported results therefore sensitive changes assumptions judgments estimates including possibility obtaining materially different results different assumptions applied We believe following critical accounting policies discussed Audit Committee Board Directors affect significant estimates judgments used preparation financial statements Revenue Recognition We generate revenue sale dental animal health medical consumable products well equipment software products services sources Provisions discounts rebates customers customer returns contra-revenue adjustments recorded based upon historical data estimates provided period related sales recognized Revenue derived sale consumable products recognized products shipped customers Such sales typically entail high-volume low-dollar orders shipped using third-party common carriers We believe shipment date appropriate point time indicating completion earnings process post-shipment obligations product price fixed determinable collection resulting receivable reasonably assured product returns reasonably estimable Revenue derived sale equipment recognized products delivered customers Such sales typically entail scheduled deliveries large equipment primarily equipment service technicians Some equipment sales require minimal installation typically completed time delivery Revenue derived sale software products recognized products shipped customers Such software generally installed customers require extensive training due nature design Revenue derived post-contract customer support software including annual support and/or training recognized period services provided Revenue derived multiple element arrangements related deferral revenue insignificant financial statements recognized follows When sell software products together related services i.e training technical support allocate revenue delivered elements using residual method based upon vendor-specific objective evidence VSOE fair value undelivered elements defer time vendor-specific evidence fair value obtained Multiple element arrangements include elements considered software consist primarily equipment related installation service We allocate revenue arrangements based relative selling prices elements applying following hierarchy first VSOE third-party evidence TPE selling price VSOE available finally estimate selling price neither VSOE TPE available VSOE exists sell deliverables separately represents actual price charged us deliverable Estimated selling 68 Table Contents price reflects best estimate selling prices deliverable would sold regularly standalone basis taking consideration cost structure business technical skill required customer location market conditions Each element standalone value accounted separate unit accounting Revenue allocated unit accounting recognized service provided product delivered Revenue derived sources including freight charges equipment repairs financial services recognized related product revenue recognized services provided Accounts Receivable Reserves The carrying amount accounts receivable reduced valuation allowance reflects best estimate amounts collected The reserve accounts receivable comprised allowance doubtful accounts sales returns In addition reviewing delinquent accounts receivable consider many factors estimating reserve including historical data experience customer types credit worthiness economic trends From time time may adjust assumptions anticipated changes factors expected affect collectability Although believe judgments estimates and/or assumptions related accounts receivable reserves reasonable making material changes judgments estimates and/or assumptions could materially affect financial results Inventories Reserves Inventories consist primarily finished goods valued lower cost market Cost determined first-in first-out method merchandise actual cost large equipment high tech equipment In accordance policy inventory valuation consider many factors including condition salability inventory historical sales forecasted sales market economic trends From time time may adjust assumptions anticipated changes factors expected affect value inventory Although believe judgments estimates and/or assumptions related inventory reserves reasonable making material changes judgments estimates and/or assumptions could materially affect financial results Goodwill Other Indefinite-Lived Intangible Assets Goodwill indefinite-lived intangible assets primarily trademarks amortized subject impairment analysis least annually Such impairment analyses goodwill require comparison fair value carrying value reporting units We regard reporting units operating segments health care distribution global dental animal health medical technology value-added services Goodwill allocated reporting units purposes preparing impairment analyses based specific identification basis For years ended December 30 2017 December 31 2016 December 26 2015 tested goodwill impairment using quantitative analysis consisting two-step approach The first step quantitative analysis consists comparison carrying value reporting units including goodwill estimated fair value reporting units using discounted cash flow methodology If step one results carrying value reporting unit exceeding fair value reporting unit would proceed step two would require us calculate amount impairment loss would record reporting unit The calculation impairment loss step two would equivalent reporting unit carrying value goodwill less implied fair value goodwill Our use discounted cash flow methodology includes estimates future revenue based upon budget projections growth rates take account estimated inflation rates We also develop estimates future levels gross operating profits projected capital expenditures Our methodology also includes use estimated discount rates based upon industry competitor analysis well factors The estimates use discounted cash flow methodology involve many assumptions management based upon future growth projections 69 Table Contents Our impairment analysis indefinite-lived intangibles consists comparison fair value carrying value assets This comparison made based review historical current forecasted sales gross profit levels well review factors may indicate potential impairment For indefinite-lived intangible assets present value technique estimates future cash flows utilized We assessed potential impairment goodwill indefinite-lived intangible assets annually beginning fourth quarter interim basis whenever events changes circumstances indicate carrying value may recoverable Some factors consider important could trigger interim impairment review include significant underperformance relative expected historical projected future operating results significant changes manner use acquired assets strategy overall business e.g decision divest business significant negative industry economic trends If determine impairment review process goodwill indefinite-lived intangible assets impaired record impairment charge consolidated statements income For years ended December 30 2017 December 31 2016 December 26 2015 results goodwill intangible impairment analysis result impairments Supplier Rebates Supplier rebates included reduction cost sales recognized period earned The factors consider estimating supplier rebate accruals include forecasted inventory purchases sales conjunction supplier rebate contract terms generally provide increasing rebates based either increased purchase sales volume Although believe judgments estimates and/or assumptions related supplier rebates reasonable making material changes judgments estimates and/or assumptions could materially affect financial results Long-Lived Assets Long-lived assets goodwill indefinite-lived intangibles evaluated impairment whenever events changes circumstances indicate carrying amount assets may recoverable estimated undiscounted future cash flows derived assets Definite-lived intangible assets primarily consist non-compete agreements trademarks trade names customer lists customer relationships intellectual property For long-lived assets used operations impairment losses recorded asset carrying amount recoverable undiscounted probability-weighted future cash flows We measure impairment loss based difference carrying amount estimated fair value When impairment exists related assets written fair value Although believe judgments estimates and/or assumptions used estimating cash flows determining fair value reasonable making material changes judgments estimates and/or assumptions could materially affect impairment analyses financial results Stock-Based Compensation Stock-based compensation represents cost related stock-based awards granted employees non-employee directors We measure stock-based compensation grant date based estimated fair value award recognize cost net estimated forfeitures compensation expense straight-line basis requisite service period Our stock-based compensation expense reflected selling general administrative expenses consolidated statements income 70 Table Contents Stock-based awards provided certain employees non-employee directors terms 2013 Stock Incentive Plan amended 2015 Non-Employee Director Stock Incentive Plan together Plans The Plans administered Compensation Committee Board Directors Prior March 2009 awards Plans principally included combination at-the-money stock options restricted stock/units Since March 2009 equity-based awards granted solely form restricted stock/units exception providing stock options employees pursuant certain pre-existing contractual obligations Grants restricted stock/units stock-based awards granted recipients specified vesting provisions In case restricted stock common stock delivered date grant subject vesting conditions In case restricted stock units common stock generally delivered following satisfaction vesting conditions We issue restricted stock/units vest solely based recipient continued service time primarily four-year cliff vesting except grants made 2015 Non-Employee Director Stock Incentive Plan primarily 12-month cliff vesting restricted stock/units vest based achieving specified performance measurements recipient continued service time primarily three-year cliff vesting With respect time-based restricted stock/units estimate fair value date grant based closing stock price With respect performance-based restricted stock/units number shares ultimately vest received recipient based upon performance measured specified targets specified period determined Compensation Committee Board Directors Although guarantee performance targets achieved estimate fair value performance-based restricted stock/units based closing stock price time grant The Plans provide adjustments performance-based restricted stock/units targets significant events including without limitation acquisitions divestitures new business ventures certain capital transactions including share repurchases restructuring costs changes accounting principles applicable laws regulations foreign exchange fluctuations certain litigation related costs material changes income tax rates Over performance period number shares common stock ultimately vest issued related compensation expense adjusted upward downward based upon estimation achieving performance targets The ultimate number shares delivered recipients related compensation cost recognized expense based actual performance metrics defined Plans Although believe judgments estimates and/or assumptions related stock-based compensation reasonable making material changes judgments estimates and/or assumptions could materially affect financial results 71 Table Contents Accounting Pronouncements Adopted In March 2016 Financial Accounting Standard Board FASB issued ASU No 2016-09 Stock Compensation Topic 718 ASU 2016-09 ASU 2016-09 contains amended guidance share-based payment accounting We adopted provisions standard first quarter 2017 Under ASU 2016-09 excess tax benefits tax deficiencies resulting difference deduction tax purposes stock-based compensation cost recognized financial reporting purposes included component income tax expense January 1 2017 Prior implementation ASU 2016-09 excess tax benefits recorded component Additional paid-in capital tax deficiencies recognized either offset accumulated excess tax benefits income statement accumulated excess tax benefits The adoption ASU 2016-09 reduced income tax expense approximately 19.6 million year ended December 30 2017 The ASU clarifies classification certain share based payment activities within statements cash flows We elected prospectively present amount excess tax benefits related stock compensation component cash flows operating activities Additionally cash payments made taxing authorities employees behalf directly withholding shares tax-withholding purposes previously included cash flows operating activities presented retrospectively cash flows financing activities within statement cash flows Recently Issued Accounting Standards In May 2014 FASB issued ASU No 2014-09 Revenue Contracts Customers ASU 2014-09 supersedes nearly existing revenue recognition guidance accounting principles generally accepted United States U.S GAAP The core principle ASU 2014-09 recognize revenues promised goods services transferred customers amount reflects consideration entity expects entitled goods services ASU 2014-09 defines five step process achieve core principle judgment estimates may required within revenue recognition process required existing U.S GAAP In August 2015 FASB issued ASU No 2015-14 Revenue Contracts Customers deferred effective date one year December 15 2017 interim annual reporting periods beginning date When effective ASU 2014-09 require us use either following transition methods full retrospective approach reflecting application standard prior reporting period option elect certain practical expedients ii modified retrospective approach cumulative effect initially adopting ASU 2014-09 recognized date adoption includes additional footnote disclosures describe nature amount timing uncertainty revenue certain costs cash flows arising contracts customers We finalized review various revenue streams within two reportable segments health care distribution ii technology value-added services We gathered data quantified amount sales type revenue stream categorized types sales business units purpose comparing currently recognize revenue new standard order quantify impact ASU We generally anticipate substantially similar performance obligations new guidance compared deliverables units account currently recognized We anticipate material changes timing amount revenues recognized health care distribution technology value-added services reportable segments Due variety product offerings technology value-added segment actual revenue recognition treatment required new standard depend contract-specific terms There impact timing revenue recognition include following 72 Table Contents We currently defer license revenue cases VSOE fair value element arrangement delivered yet customer support Under Accounting Standards Codification ASC 606 concept VSOE eliminated cases revenue deferred due lack standalone selling price As recognize certain revenue related software license earlier current practice Certain upfront fees related service arrangements currently deferred recognized estimated customer life Under ASC 606 period recognize fees reduced Revenue related term licenses currently recognized license term Under ASC 606 license recognized upon delivery license renewal We currently expense contract acquisition costs The new requirement defer incremental contract acquisition costs recognize term initial contract anticipated renewal contracts costs relate require us capitalize additional costs We utilize practical expedient permitting expensing costs obtain contract expected amortization period one year less typically result expensing commissions products services except software support contracts In cases generally recognize revenue related technology value-added contracts earlier current practice certain contract acquisition costs recognized later current practice However believe impact material segments consolidated financial statements As December 31 2017 expect adopt standard modified retrospective basis recognize immaterial adjustment retained earnings reflecting cumulative impact described accounting changes In February 2016 FASB issued ASU No 2016-02 Leases Topic 842 ASU 2016-02 ASU 2016-02 contains guidance accounting leases requires lease assets liabilities associated rights obligations recognized Company balance sheet ASU 2016-02 focuses lease assets lease liabilities lessees classified operating leases previous generally accepted accounting principles For leases term 12 months less lessee permitted make accounting policy election class underlying asset recognize lease assets lease liabilities ASU 2016-02 require disclosures regarding amount timing uncertainty cash flows arising leases The standard requires use modified retrospective approach effective interim annual periods beginning December 15 2018 Early adoption permitted We currently exploring methods use gather process operating lease data worldwide consolidated level In January 2017 FASB issued ASU No 2017-04 Intangibles-Goodwill Other Topic 350 ASU 2017-04 ASU 2017-04 eliminates step two goodwill impairment test thereby eliminating requirement calculate implied fair value reporting unit ASU 2017-04 require us perform annual goodwill impairment test comparing fair value reporting units carrying value units If carrying value exceeds fair value required recognize impairment charge however impairment charge exceed amount goodwill allocated reporting unit ASU 2017-04 required implemented prospective basis fiscal years beginning December 15 2019 We expect requirements ASU 2017-04 material impact consolidated financial statements In May 2017 FASB issued ASU No 2017-09 Compensation-Stock Compensation Topic 718 Scope Modification Accounting ASU 2017-09 ASU 2017-09 clarifies guidance determining changes terms conditions share-based payment awards require entity apply modification accounting ASU 2017-09 requires modification accounting fair value vesting conditions equity liability classification award immediately change terms conditions award ASU 2017-09 required implemented prospective basis fiscal years beginning December 15 2017 73 Table Contents We expect requirements ASU 2017-09 material impact consolidated financial statements In August 2017 FASB issued ASU No 2017-12 Derivatives Hedging Topic 815 ASU 2017-12 simplifies requirements hedge accounting closely aligns hedge accounting risk management activities increases transparency scope results hedging activities This ASU amends presentation disclosure requirements changes assess effectiveness hedging relationships This ASU make financial nonfinancial hedging strategies eligible hedge accounting ASU 2017-12 required implemented fiscal years beginning December 15 2018 interim periods within fiscal years Early adoption ASU 2017-12 permitted interim period issuance ASU We expect requirements ASU 2017-12 material impact consolidated financial statements In June 2016 FASB issued ASU No 2016-13 Financial Instruments-Credit Losses Topic 326 Measurement Credit Losses Financial Instruments requires measurement recognition expected credit losses financial assets held amortized cost This ASU effective interim annual reporting periods beginning December 15 2019 early adoption permitted interim annual reporting periods beginning December 15 2018 This ASU required adopted using modified retrospective basis cumulative-effect adjustment retained earnings beginning first reporting period guidance ASU effective Based upon level makeup financial asset portfolio past loan loss activity current known activity regarding outstanding loans expect ASU material impact results consolidated financial statements 74 Table Contents ITEM 7A Quantitative Qualitative